Advertisement

Annals of Hematology

, Volume 97, Issue 9, pp 1727–1729 | Cite as

Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?

  • Narendranath Epperla
  • Ariel Kleman
  • Matthew Karafin
  • Patrick Foy
Letter to the Editor
  • 141 Downloads

Dear Editor,

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by a multisystem vascular dyscrasia leading to severe and recurrent epistaxis and gastrointestinal (GI) hemorrhages from mucocutaneous telangiectases and development of arteriovenous malformations (AVM), most commonly in the lung, liver, brain, and spine [1, 2, 3, 4]. In patients with HHT, vascular endothelial growth factor (VEGF) levels in circulation are elevated [4] forming the basis for utilization of bevacizumab, a VEGF inhibitor, in this disease state. Intravenous (IV) administration of bevacizumab has been shown to be effective in improving epistaxis and telangiectasias, reducing the need for red blood cell (RBC) transfusions, and improvement in the high output cardiac failure [5, 6, 7, 8]. However, it is unclear as to the optimal dosing strategy of IV bevacizumab in patients with HHT. Hence, we aimed to determine whether re-treatment strategy or extended dosing...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Larson AM (2003) Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 36(2):149–158CrossRefPubMedGoogle Scholar
  2. 2.
    Shovlin CL, Letarte M (1999) Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 54(8):714–729CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Begbie ME, Wallace GM, Shovlin CL (2003) Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 79(927):18–24CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818–828PubMedGoogle Scholar
  5. 5.
    Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143–2144CrossRefPubMedGoogle Scholar
  6. 6.
    Epperla N, Hocking W (2015) Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 13(1):32–35CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P (2016) Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol 91(6):E313–E314CrossRefPubMedGoogle Scholar
  8. 8.
    Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948–955CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of HematologyThe Ohio State UniversityColumbusUSA
  2. 2.Division of Hematology and OncologyMedical College of WisconsinMilwaukeeUSA
  3. 3.Department of MedicineMedical College of WisconsinMilwaukeeUSA
  4. 4.Department of PathologyMedical College of WisconsinMilwaukeeUSA
  5. 5.Medical Sciences InstituteBloodCenter of WisconsinMilwaukeeUSA

Personalised recommendations